IPOGrid
0001054102
IPO filing research
INTERPACE BIOSCIENCES, INC.
Surgical & Medical Instruments & Apparatus · IDXG
follow-on
amended
OTC
S-1/A
INTERPACE BIOSCIENCES, INC. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1/A on 2026-10-01. Current deal snapshot: exchange OTC.
Filing Timeline
SEC EDGAR
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
Range $6.00 to $7.00 · 3,100,000 shares
Common Stock · Exchange Nasdaq · Ticker IDXG · Over-allotment 465,000 · Use of proceeds For working capital, capital expenditures, and general corporate purposes, including potential development of a new test and in-licensing opportunities
2026-10-01 · 0001493152-26-045187
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
First tracked pre-IPO filing for this issuer.
Gross proceeds $20,000,000
Common Stock · Exchange Nasdaq · Ticker IDXG · Use of proceeds for working capital, capital expenditures and other general corporate purposes
2026-09-25 · 0001493152-26-044208
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
2026-07-22 · 0001493152-26-034243
RW
withdrawn
Withdrawal request
Issuer requested withdrawal of the registration statement.
Follows 424B4 and ends the active registration process.
2022-06-16 · 0001493152-22-016962
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Price $6.65 · 4,200,045 shares · Gross proceeds $27,930,299
common · Exchange OTCQX · Ticker IDXG · Flags self_underwritten
2022-01-13 · 0001493152-22-001088
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1/A and marks the registration effective.
2022-01-12 · 9999999995-22-000119
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
4,184,707 shares
Common Stock · Exchange OTCQX · Ticker IDXG
2022-01-07 · 0001493152-22-000718
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
4,184,707 shares
Common Stock · Exchange OTCQX · Ticker IDXG
2022-01-03 · 0001493152-22-000146
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows 424B5 in the pre-IPO sequence.
common stock · Exchange OTCQX · Ticker IDXG · Underwriters self-underwritten
2021-12-06 · 0001493152-21-030511
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Gross proceeds $4,800,000
Common Stock · Exchange Nasdaq Capital Market · Ticker IDXG · Use of proceeds general corporate purposes · Underwriters Oppenheimer & Co. Inc.
2019-09-20 · 0001493152-19-014377
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Price $0.75 · 9,333,334 shares · Gross proceeds $7,000,000
COMMON · Exchange NASDAQ CAPITAL MARKET · Ticker IDXG · Over-allotment 1,400,000
2019-01-28 · 0001493152-19-001046
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Common · Exchange Nasdaq Capital Market · Ticker IDXG · Use of proceeds for working capital, capital expenditures, business development, research and development, and acquisition of new technologies and businesses
2019-01-25 · 0001493152-19-000930
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B4 and marks the registration effective.
2018-10-19 · 9999999995-18-002672
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Price $1.10 · 9,900,000 shares · Gross proceeds $13,700,000
Common Stock · Exchange Nasdaq Capital Market · Ticker IDXG · Over-allotment 1,875,000 · Pre-funded warrants to purchase 2,600,000 shares and common warrants to purchase 12,500,000 shares · Use of proceeds to cover offering expenses and for general corporate purposes · Flags warrants · Underwriters Maxim Group LLC
2017-06-16 · 0001493152-17-006768
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1/A and marks the registration effective.
2017-06-15 · 9999999995-17-001551
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Gross proceeds $14,950,000
Common Stock and Pre-Funded Warrants · Warrants exercisable at 120% of public offering price · Use of proceeds General corporate purposes, including working capital and potential acquisitions
2017-06-13 · 0001493152-17-006560
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $1.75 · 7,428,571 shares · Gross proceeds $14,950,000
Common Stock · Exchange NASDAQ · Ticker IDXG · Over-allotment 1,114,286 · Common Stock and Warrants · Common warrants exercisable at 120% of public offering price, 5-year term · Use of proceeds Net proceeds to be used for working capital, trade payables, legacy CSO obligations, and general corporate purposes · Flags warrants · Underwriters MaximGroup LLC
2017-06-13 · 0001493152-17-006543
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
common stock of Interpace Biosciences, Inc. · Exchange Nasdaq Capital Market · Ticker IDXG · Over-allotment 942,408 · Pre-funded warrants with $0.01 exercise price, exercisable after 6 months · Use of proceeds working capital · Flags units, warrants · Underwriters Maxim Group LLC
2017-06-07 · 0001493152-17-006276
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows 424B5 in the pre-IPO sequence.
common stock and pre-funded warrants · Exchange Nasdaq Capital Market · Ticker IDXG · Warrants to purchase 4% of shares sold at 120% of public offering price, cashless exercise, 6-month lock-up · Use of proceeds Proceeds will be used for working capital and general corporate purposes · Underwriters MaximGroup LLC
2017-05-22 · 0001493152-17-005686
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Price $3.00 · 1,200,000 shares · Gross proceeds $3,600,000
Common Stock · Exchange Nasdaq · Ticker IDXG · Over-allotment 108,000 · Use of proceeds for working capital, repayment of indebtedness and other liabilities and general corporate purposes · Underwriters Maxim Group LLC
Interpace Biosciences, Inc. filed a 424B5 prospectus supplement on February 3, 2017, detailing financial data and risks associated with its IPO. The filing includes summary financials showing a reverse stock split on December 28, 2016, and highlights significant operating losses, negative working capital, and liquidity challenges. The company faces risks related to its ability to meet debt obligations, including a secured promissory note with the RedPath Equityholder Representative, and substantial doubts about its ability to continue as a going concern. The filing also outlines ongoing financial struggles, reliance on future financing, and obligations to Asuragen and RedPath equityholders.
2017-02-03 · 0001437749-17-001584
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Common Stock · Exchange Nasdaq · Ticker IDXG · Use of proceeds working capital, repayment of indebtedness and other liabilities and general corporate purposes · Underwriters Maxim Group LLC
Interpace Biosciences, Inc. filed a 424B5 prospectus supplement on 2017-02-02, detailing financial data post-reverse stock split and risks related to liquidity, debt obligations, and operational sustainability. The filing includes summary financials showing operating losses, cash flow challenges, and recent equity offerings to address capital needs. Key risks include inability to meet debt payments, reliance on future financing, and potential bankruptcy. The company also faces ongoing obligations from past acquisitions and unresolved vendor disputes.
2017-02-02 · 0001437749-17-001540
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Price $4.69 · 855,000 shares · Gross proceeds $4,009,950
Common Stock · Exchange Nasdaq Capital Market · Ticker IDXG · Each unit consists of one share of common stock and one warrant · Warrants to purchase 855,000 shares of common stock, exercisable at $4.69, expiring in 5 years · Flags units · Underwriters Maxim Group LLC
Interpace Biosciences, Inc. is conducting a registered direct offering of 855,000 shares of common stock at $4.69 per share, with accompanying warrants. The company plans to use net proceeds for working capital, debt repayment, and settling $1.028 million in severance obligations to former executives. The filing highlights ongoing financial challenges, including defaults on lease payments, credit agreements, and vendor obligations, as well as significant current liabilities ($19.9 million) and negative working capital. The company remains in default on multiple obligations and faces uncertainties around future liquidity and viability as a going concern.
2017-01-24 · 0001437749-17-001043
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Price $6.81 · 630,000 shares · Gross proceeds $4,290,300
Common Stock · Exchange Nasdaq Capital Market · Ticker IDXG · Use of proceeds Working capital, repayment of indebtedness, and general corporate purposes
The current filing for Interpace Biosciences, Inc. details financial results through September 30, 2016, following a December 2016 reverse stock split. The company reports significant operating losses, with a $13.1 million loss for the nine months ended September 30, 2016, and $1.7 million in cash balances as of that date. Key risks include inability to meet principal payments on a $1.3 million note, going concern uncertainties, and dependence on future financing. The filing also highlights ongoing obligations to Asuragen and RedPath equityholders, as well as challenges in commercializing molecular diagnostics.
2017-01-05 · 0001437749-17-000273
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Price $0.53 · Range $0.53 to $0.52 · 2,000,000 shares · Gross proceeds $1,892,000
Common Stock · Exchange Nasdaq Capital Market · Ticker IDXG · Prefunded warrants to purchase 1,600,000 shares at $0.52 each, exercisable at $0.01 per share · Use of proceeds Use of proceeds for working capital, repayment of indebtedness, and general corporate purposes · Underwriters Maxim Group LLC
Interpace Biosciences, Inc. faces significant financial risks as it prepares for its IPO, including inability to meet a $1.3 million principal payment on a secured promissory note by December 31, 2016, which could trigger foreclosure or bankruptcy. The company reports substantial doubts about its ability to continue as a going concern due to operating losses, negative working capital, and insufficient liquidity. It relies on raising equity or debt capital to avoid default, with ongoing obligations from its 2014 acquisition of RedPath and previous CSO business sale. The molecular diagnostics business remains unprofitable, with expected continued losses and reliance on future revenue growth and capital raises.
2016-12-21 · 0001437749-16-043658
424B5
priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Gross proceeds $5,000,000
Common Stock · Exchange NASDAQ · Ticker PDII · Use of proceeds General corporate purposes, including working capital and product development · Flags best_efforts · Underwriters Cantor Fitzgerald & Co.
Interpace Biosciences, Inc. (PDI, Inc.) filed a 424B5 registration statement disclosing pro forma financial statements following the planned sale of its Commercial Services Business to Publicis Touchpoint Solutions, Inc. for up to $33 million, including contingent earn-out payments. The filing includes adjusted pro forma balance sheets and income statements assuming the asset sale closed in 2013 and 2015, showing reduced revenues and expenses from the divested business, increased cash balances, and contingent liabilities. The company also disclosed tax implications, debt restructuring, and adjustments to stockholder equity.
2015-11-02 · 0001054102-15-000051
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2015-10-09 · 9999999995-15-002701
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2011-07-15 · 9999999995-11-002151
Comparable Deals
4 comparable deals
Healthcare & BiotechMicro (<$50M)Last 18 months
Only 0 strict matches; expanded to 4 using nearest neighbors.
Recent News
No recent news stored for this issuer.